Tesamorelin, 2mg

Tesamorelin 2 mg provides one individually sealed lyophilised vial of the synthetic GHRH analogue, suited for preclinical GH axis research, GHRHR agonist studies, and controlled laboratory protocols requiring a single 2 mg research vial.

Tesamorelin’s trans-3-hexenoic acid N-terminal modification confers DPP-IV resistance and an extended half-life of approximately 26–38 minutes compared to around 7 minutes for native GHRH, while preserving full GHRHR agonist activity. The single-vial format is suitable for smaller-scale experiments, pilot studies, or protocols that do not require a multi-vial kit.